CA2386248A1 - Mutants il13 - Google Patents

Mutants il13 Download PDF

Info

Publication number
CA2386248A1
CA2386248A1 CA002386248A CA2386248A CA2386248A1 CA 2386248 A1 CA2386248 A1 CA 2386248A1 CA 002386248 A CA002386248 A CA 002386248A CA 2386248 A CA2386248 A CA 2386248A CA 2386248 A1 CA2386248 A1 CA 2386248A1
Authority
CA
Canada
Prior art keywords
leu
hill3
mutant
hil13
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386248A
Other languages
English (en)
Inventor
Waldemar Debinski
Jeffrey P. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2386248A1 publication Critical patent/CA2386248A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

L'invention concerne des molécules d'interleukine 13 humaine mutantes faisant preuve d'une spécificité différente pour le récepteur limité de l'IL13 (indépendant de l'IL14). Les molécules de l'hIL13 mutantes sont constituées de celles formées par substitution des restes d'acides aminés présents dans les zones sous forme d'alpha hélice d'hIL13 native avec d'autres restes d'acides aminés. Certains mutants conservent la capacité de se lier et d'assurer la signalisation à travers les récepteurs d'IL13 au détriment d'autres mutants.
CA002386248A 1999-10-06 2000-10-05 Mutants il13 Abandoned CA2386248A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15793499P 1999-10-06 1999-10-06
US60/157,934 1999-10-06
PCT/US2000/027567 WO2001025282A1 (fr) 1999-10-06 2000-10-05 Mutants il13

Publications (1)

Publication Number Publication Date
CA2386248A1 true CA2386248A1 (fr) 2001-04-12

Family

ID=22565965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386248A Abandoned CA2386248A1 (fr) 1999-10-06 2000-10-05 Mutants il13

Country Status (5)

Country Link
EP (1) EP1222212A4 (fr)
JP (1) JP2003511019A (fr)
AU (1) AU7863900A (fr)
CA (1) CA2386248A1 (fr)
WO (1) WO2001025282A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
AU2001288405B8 (en) * 1998-04-03 2007-06-14 The Penn State Research Foundation Amino acid substitution mutants of interleukin 13
EP1141286B1 (fr) 1998-12-14 2006-10-18 Genetics Institute, LLC Chaine de recepteurs de cytokine
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
EP1263785A2 (fr) * 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation de l'activite de il-13 au moyen de molecules il-13 qui sont des antagonistes ou des agonistes de il-13
EA200400658A1 (ru) * 2001-11-09 2004-10-28 Неофарм, Инк. Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты)
FI3718564T3 (fi) * 2003-12-23 2023-12-15 Genentech Inc Uusia anti-IL 13 -vasta-aineita ja niiden käyttöjä
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US9072716B2 (en) 2005-04-15 2015-07-07 The United States of America, as represented by the Secretary Department of Health by Human Servies Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
WO2013112871A1 (fr) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides d'il-13 thérapeutiques
CN116041551A (zh) 2013-09-24 2023-05-02 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EP1206288B1 (fr) * 1999-08-02 2007-01-10 The Regents Of The University Of Michigan Effecteurs radiatifs cibles exempts de fibres

Also Published As

Publication number Publication date
EP1222212A1 (fr) 2002-07-17
WO2001025282A1 (fr) 2001-04-12
JP2003511019A (ja) 2003-03-25
AU7863900A (en) 2001-05-10
EP1222212A4 (fr) 2005-05-04

Similar Documents

Publication Publication Date Title
US6576232B1 (en) IL13 mutants
JP4202417B2 (ja) Ｉｌ−１３受容体特異的キメラタンパク質およびその用途
US6428788B1 (en) Compositions and methods for specifically targeting tumors
US6296843B1 (en) Mutagenized IL 13-based chimeric molecules
EP0754192B1 (fr) Ligands et molecules chimeriques a permutation circulaire
CA2411470C (fr) Fusions et conjugues de recepteurs de lymphocytes t et procedes d'utilisation correspondants
US7750136B2 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
US6884603B2 (en) Nucleic acids encoding IL13 mutants
AU2001288405B2 (en) Amino acid substitution mutants of interleukin 13
CA2386248A1 (fr) Mutants il13
US6630576B2 (en) Amino acid substitution mutants of interleukin 13
CA2333923A1 (fr) Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15
US20030129132A1 (en) IL-13 receptor specific chimeric proteins & uses thereof
AU2001288405A1 (en) Amino acid substitution mutants of interleukin 13

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued